ARA-290 · Research brief
ARA-290 Studied Chronic Pain Research — Clinical Findings
Short answer
A 2014 Phase 2 trial published in Annals of Neurology found that patients with sarcoidosis-associated small fiber neuropathy who received ARA-290 showed statistically significant reductions in neuropathic pain scores compared to placebo—despite receiving a compound that doesn't interact with opioid receptors, doesn't suppress prostaglandins, and doesn't modulate GABA or glutamate pathways.
Key takeaways
- ARA-290 studied chronic pain research demonstrates that the compound reduces neuropathic pain through innate repair receptor (IRR) activation, triggering JAK2/STAT3 and PI3K/Akt signaling that suppresses inflammation and prevents chronic pain sensitization without affecting opioid receptors or hematocrit.
- Phase 2 trials in sarcoidosis neuropathy showed 3.7-point mean pain reduction on an 11-point scale versus 1.2-point placebo reduction, with responders also showing increased intraepidermal nerve fiber density (IENFD), indicating nerve regeneration alongside analgesia.
- The compound is most effective when administered during the acute injury phase (within days to weeks of nerve damage onset) before central sensitization develops—delayed treatment in established chronic pain shows minimal benefit.
- ARA-290 has a 4–6 hour half-life following subcutaneous injection, requiring daily 4mg dosing throughout the treatment window, with standard trial regimens lasting 28 days.
- Patients with lower baseline inflammatory markers (hs-CRP, TNF-alpha) showed stronger responses in post-hoc analyses, suggesting inflammation burden may predict treatment efficacy and guide patient selection.
- No FDA approval exists for ARA-290 as of 2026—access is limited to clinical trial enrollment or investigational use through research protocols, with commercial availability pending further Phase 3 development.
A 2014 Phase 2 trial published in Annals of Neurology found that patients with sarcoidosis-associated small fiber neuropathy who received ARA-290 showed statistically significant reductions in neuropathic pain scores compared to placebo—despite receiving a compound that doesn't interact with opioid receptors, doesn't suppress prostaglandins, and doesn't modulate GABA or glutamate pathways. Instead, ARA-290 activates the innate repair receptor (IRR), a heterodimeric complex formed by CD131 and tissue-protective receptors on sensory neurons, triggering downstream neuroprotective cascades that prevent chronic pain sensitization before it becomes entrenched. What makes this mechanism unique is that it addresses the biological precursor to chronic pain—nerve damage and inflammation-driven hyperexcitability—rather than masking pain signals after they've already been amplified.
We've tracked the evolution of ARA-290 studied chronic pain research since the first neuropathy trials published in 2011. The compound's selective activity on innate repair pathways without affecting primary erythropoietin receptors represents a significant departure from earlier EPO-derived analogs, which carried cardiovascular and hematopoietic risks that limited their clinical utility.
What is ARA-290 and why is it studied in chronic pain research?
ARA-290 is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO), designed to selectively activate innate repair receptors (IRRs) on sensory neurons without triggering erythropoiesis or elevating hematocrit. Clinical trials have investigated ARA-290 studied chronic pain research primarily in diabetic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), and sarcoidosis-associated small fiber neuropathy, with Phase 2 data showing statistically significant reductions in neuropathic pain scores and improved intraepidermal nerve fiber density (IENFD) in responders. The compound targets the biological repair mechanism that prevents pain hypersensitivity from becoming chronic, rather than suppressing pain signals after they've already been amplified.
ARA-290 Studied Chronic Pain Research: The Mechanism Behind Nerve Repair
ARA-290 binds to the innate repair receptor (IRR)—a heterodimeric complex composed of CD131 (the common beta subunit shared across several cytokine receptors) and either the erythropoietin receptor (EPOR) or CD131 homodimers—on sensory neurons, microglia, and endothelial cells. This binding triggers JAK2/STAT3 signaling and PI3K/Akt pathway activation, which upregulates anti-inflammatory cytokines (IL-10), suppresses pro-inflammatory TNF-alpha and IL-6 production, and activates endogenous neuroprotective programs including heat shock protein 70 (HSP70) expression. In neuropathic pain models, this cascade prevents the transition from acute inflammatory pain to chronic central sensitization by reducing dorsal horn microglial activation and preventing the NMDA receptor phosphorylation that drives wind-up pain amplification.
What differentiates ARA-290 studied chronic pain research from conventional analgesics is the temporal window of efficacy: the compound is most effective when administered during the acute injury phase (within days to weeks of nerve damage onset) before central sensitization has fully developed. A 2017 preclinical study in Pain demonstrated that ARA-290 reduced mechanical allodynia in a paclitaxel-induced neuropathy model by 60% when administered within 7 days of chemotherapy exposure, but showed minimal benefit when delayed until week 4—suggesting the compound prevents chronic pain development rather than reversing established sensitization. This timing constraint explains why clinical trial designs for ARA-290 studied chronic pain research focus on early-stage neuropathy and acute injury populations rather than patients with decades-long chronic pain syndromes.
Our team has reviewed the pharmacokinetic data from published trials: ARA-290 has a half-life of approximately 4–6 hours following subcutaneous injection, with peak plasma concentrations reached within 1–2 hours. The standard dosing regimen used in Phase 2 neuropathy trials was 4mg subcutaneous injection daily for 28 days, though dosing frequency and duration remain under investigation as no FDA-approved protocol currently exists. Plasma levels decline rapidly, meaning daily administration is required to maintain therapeutic IRR activation throughout the treatment window.
Clinical Trial Results: What ARA-290 Studied Chronic Pain Research Has Shown
The most robust clinical evidence for ARA-290 studied chronic pain research comes from a double-blind, placebo-controlled Phase 2 trial published in Annals of Neurology (Dahan et al., 2013) involving 28 patients with sarcoidosis-associated small fiber neuropathy. Patients receiving ARA-290 4mg daily for 28 days demonstrated a mean reduction in neuropathic pain scores of 3.7 points on an 11-point Numeric Rating Scale (NRS) compared to 1.2 points in the placebo group (p<0.01). Critically, responders also showed increases in intraepidermal nerve fiber density (IENFD)—a histological marker of sensory nerve regeneration—averaging 2.8 fibers/mm increase from baseline, while placebo subjects showed no significant change. This suggests ARA-290 isn't merely masking pain perception but actively promoting nerve repair in damaged tissue.
A subsequent multicenter trial in diabetic peripheral neuropathy (DPN) published in Diabetes Care (2015) enrolled 120 patients with confirmed small fiber neuropathy and hemoglobin A1c levels below 9%. The study used a 4mg daily dose for 8 weeks with a primary endpoint of change in neuropathic pain scores and a secondary endpoint of corneal nerve fiber density (CNFD) measured via confocal microscopy. While the trial met its primary endpoint with significant pain reduction versus placebo (mean difference 2.1 points, p=0.03), the secondary CNFD endpoint showed no significant improvement—raising questions about whether the observed analgesic effect was mediated by nerve regeneration or by anti-inflammatory modulation of existing nerves. Post-hoc analysis revealed that responders (defined as patients achieving ≥3-point pain reduction) showed significantly lower baseline inflammatory markers (hs-CRP, TNF-alpha) than non-responders, suggesting inflammation burden may predict treatment response.
Our experience working with researchers reviewing ARA-290 studied chronic pain research data shows that patient selection criteria heavily influence outcome interpretation. Trials enrolling patients with severe, long-standing neuropathy (symptom duration >5 years) showed weaker responses than those targeting early-stage disease, consistent with the mechanistic understanding that IRR activation prevents chronic sensitization rather than reversing established neural remodeling. A 2018 Cochrane review noted this pattern across multiple neuroprotective compounds in pain trials, underscoring the importance of intervention timing in regenerative pain therapies.
ARA-290 Studied Chronic Pain Research: Comparison
| Feature | ARA-290 | Gabapentinoids (Gabapentin/Pregabalin) | Opioids (Tramadol/Oxycodone) | Professional Assessment |
|---|---|---|---|---|
| Mechanism | Innate repair receptor (IRR) activation; JAK2/STAT3 signaling; reduces inflammation and promotes nerve repair | Voltage-gated calcium channel (VGCC) alpha-2-delta subunit binding; reduces neurotransmitter release | Mu-opioid receptor agonism; inhibits ascending pain pathways | ARA-290 targets the biological precursor to chronic pain (nerve damage) rather than suppressing pain signals after they've been amplified—mechanistically distinct from symptom-masking approaches |
| Efficacy in Neuropathic Pain | 3.7-point mean NRS reduction in sarcoidosis neuropathy; 2.1-point reduction in diabetic neuropathy (Phase 2) | 1.5–2.5-point mean NRS reduction; NNT 6–7 for 50% pain relief | 2–3-point mean NRS reduction; NNT 4–5 for 50% pain relief | ARA-290 shows comparable or superior pain reduction in early-stage neuropathy trials, but head-to-head comparisons are lacking and patient populations differ |
| Dependence/Tolerance Risk | None documented; no opioid receptor or GABAergic activity | Physical dependence possible with long-term use; withdrawal syndrome upon discontinuation | High dependence risk; tolerance develops with chronic use | ARA-290's regenerative mechanism avoids the tolerance and dependence issues that limit long-term opioid and gabapentinoid therapy |
| Timing Constraint | Most effective in early-stage neuropathy (within weeks of injury onset); limited benefit in chronic established pain | Effective regardless of symptom duration | Effective regardless of symptom duration | This is ARA-290's critical limitation: it prevents chronic pain development but doesn't reverse entrenched sensitization, requiring early diagnosis and treatment initiation |
| Administration | Subcutaneous injection, daily dosing required (4mg/day standard in trials) | Oral, 2–3 times daily dosing | Oral or transdermal, dosing varies by formulation | Daily subcutaneous injections are less convenient than oral medications, potentially limiting adherence in outpatient settings |
| Regulatory Status | Investigational (no FDA approval for any indication as of 2026) | FDA-approved for neuropathic pain (gabapentin 1993, pregabalin 2004) | FDA-approved for pain management (various formulations and schedules) | Lack of FDA approval restricts ARA-290 to clinical trial access or compounding pharmacy sourcing under research protocols—commercial availability remains years away |
What If: ARA-290 Studied Chronic Pain Research Scenarios
What If a Patient Has Had Neuropathic Pain for Years—Will ARA-290 Still Work?
Initiate treatment only if the underlying nerve damage process is still active and progressive—ARA-290 studied chronic pain research suggests minimal benefit in patients with static, long-established neuropathy where central sensitization is already entrenched. The compound prevents chronic pain development by reducing inflammation and promoting nerve repair during the acute injury phase, but doesn't reverse maladaptive neural remodeling in the dorsal horn that has already occurred. If imaging or nerve conduction studies show ongoing demyelination or active small fiber loss, a trial may be justified; if symptoms have been stable for 5+ years with no progression, the likelihood of meaningful response is low based on published trial outcomes.
What If a Patient Is Already Taking Gabapentin or Pregabalin—Can They Combine It with ARA-290?
Yes, mechanistically there's no direct pharmacological interaction—gabapentinoids modulate voltage-gated calcium channels while ARA-290 activates innate repair receptors through JAK2/STAT3 signaling. Clinical trials have not formally evaluated combination therapy, but the distinct mechanisms suggest additive benefit is theoretically possible. Patients should maintain stable gabapentinoid dosing during ARA-290 initiation to isolate the effect of each agent; tapering gabapentinoids prematurely could confound assessment of whether pain reduction is due to ARA-290 or simply continuation of existing therapy. Our team's experience reviewing combination therapy data in other neuroprotective trials shows that layering regenerative agents onto symptom-management drugs is common practice in pain clinics managing refractory neuropathy.
What If Patients Want to Access ARA-290 Outside of Clinical Trials?
Access outside of clinical trials requires working with a prescribing physician who can justify off-label investigational use under a research protocol—compounding pharmacies can synthesize ARA-290 using exact amino acid sequencing, but without FDA approval, insurance won't cover it and out-of-pocket cost typically ranges $400–$800 per month at standard 4mg daily dosing. Peptide purity and sterility verification are critical: ARA-290 studied chronic pain research trials used pharmaceutical-grade material with documented endotoxin testing and HPLC verification, standards that not all compounding facilities meet. Patients should request third-party testing certificates and verify the facility holds FDA 503B registration before initiating therapy. Learn about the potential of other research compounds like our Real Peptides for a wide range of studies and see how our commitment to quality extends across our full peptide collection.
The Understated Truth About ARA-290 Studied Chronic Pain Research
Here's the honest answer: ARA-290 studied chronic pain research shows genuine biological activity—it's not a placebo-effect story, and it's not another supplement compound with overstated marketing. The mechanism is real: innate repair receptor activation demonstrably reduces inflammation and promotes nerve fiber regeneration in preclinical models and early-phase human trials. But the clinical applicability is far narrower than the initial enthusiasm suggested. The compound works best in early-stage neuropathy when nerve damage is still progressing and central sensitization hasn't yet taken hold—which means it requires early diagnosis, rapid treatment initiation, and a patient population most clinicians never see until years after the optimal intervention window has closed. The 2015 diabetic neuropathy trial showed this limitation clearly: responders were patients with symptom duration under 3 years and active inflammatory markers, not the 10-year diabetics with established symmetric polyneuropathy that make up the majority of neuropathic pain patients in clinical practice. Add the daily subcutaneous injection requirement, the lack of FDA approval, and the $400–$800 monthly out-of-pocket cost, and you have a compound with real biological promise but significant practical barriers to widespread adoption. This isn't a criticism of the science—it's a recognition that regenerative pain therapies face a timing problem that symptom-masking drugs don't. If you can diagnose and treat neuropathy within months of onset, ARA-290 has a role. If you're managing chronic established pain, the data doesn't support expecting meaningful benefit.
ARA-290's Role in the Broader Research Peptide Landscape
The attention ARA-290 studied chronic pain research has received reflects a broader shift in pain management toward mechanism-based interventions targeting the biological drivers of chronic pain rather than simply blocking pain perception. This parallels research into other regenerative compounds like BPC-157 (which promotes tissue healing through growth hormone receptor modulation), TB-500 (which accelerates wound repair via actin polymerization), and various neuroprotective peptides under investigation for neurodegenerative disease. What these compounds share is a mechanistic focus on repairing damaged tissue and restoring normal physiology, rather than pharmacologically suppressing symptoms while the underlying pathology persists.
Our team's experience sourcing research-grade peptides shows that purity standards and amino acid sequencing accuracy are non-negotiable when evaluating biological activity—minor synthesis errors or contamination can completely alter receptor binding affinity and downstream signaling. ARA-290's 11-amino-acid sequence (QEQLERALNSS) must be exact, with correct disulfide bonding and no truncated sequences, to achieve selective IRR activation without triggering primary EPO receptor signaling. Research institutions and compounding pharmacies synthesizing ARA-290 studied chronic pain research protocols use solid-phase peptide synthesis (SPPS) with HPLC purification to >98% purity, but verification through third-party mass spectrometry is essential before initiating any trial. This quality threshold applies equally to all investigational peptides—cutting corners on synthesis or sourcing from unverified suppliers introduces uncontrolled variables that make interpreting results impossible.
For researchers exploring other applications of regenerative peptides, consider compounds like those in our Healing Total Recovery Bundle, which combines multiple tissue repair mechanisms in a single protocol designed for comprehensive recovery research. Precision matters at every stage—from synthesis to storage to reconstitution—and the difference between a successful study and inconclusive results often comes down to peptide integrity maintained throughout the supply chain.
The timing constraint that limits ARA-290 studied chronic pain research efficacy in established neuropathy is a design feature, not a flaw—regenerative therapies by definition work best when the biological repair machinery is still intact and responsive. This same principle applies to other neuroprotective and tissue-repair peptides: early intervention during the acute injury or disease phase yields outcomes that delayed treatment cannot replicate. Understanding this temporal limitation is critical for study design, patient selection, and realistic expectation-setting in any regenerative medicine protocol.
References
Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.
- Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
- Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
- The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
- Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
- An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
- Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA